New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:01 EDTGALTGalectin Therapeutics presents preclinical data on GR-MD-02
Galectin Therapeutics presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease Annual Meeting in Boston, MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of non-alcoholic steatohepatitis, or fatty liver disease. These new data help to further explain the mechanism of action of GR-MD-02, showing that this galectin inhibitor affects multiple pathways involved with both the prevention and reversal of fibrosis in NASH pathology. The new data show that Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were dramatically reduced to barely detectable levels following treatment with GR-MD-02. Elevated expression of iNOS, an important inflammatory mediator, and CD36, a scavenger receptor involved in the pathogenesis of NASH, were markedly reduced following treatment with GR-MD-02.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
10:00 EDTGALTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:27 EDTGALTOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTGALTGalectin Therapeutics downgraded to Hold from Buy at Aegis
Subscribe for More Information
July 30, 2014
11:14 EDTGALTHigh option volume stocks
High option volume stocks: EXAM ASML EWY TQNT NFX RFMD RATE BPI GALT ZLTQ
09:24 EDTGALTGalectin Therapeutics comments on reactions to GR-MD-02 phase 1 results
Galectin Therapeutics commented on market and social media reactions to the announced results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis. The company stated, "While the results of the clinical trial were positive, the market reacted negatively to this report. We believe the reaction was fueled in part by certain commentary on social media sites and the Internet and we strongly disagree with these interpretations of our data". "There is a large amount of scientific literature showing galectin-3 is a critical protein in fibrosis". "Certain commentators on social media labeled the second cohort results, 'a flop.' This is simply not accurate. The primary endpoints for the phase 1 trial have always been safety and pharmacokinetics and have been successfully met for each cohort completed." "While the phase 1 trial is still ongoing, we deem the phase 1 clinical trial a success up to this point." "Exploratory biomarkers were included to aid in the design of a phase 2 program that will be focused on showing efficacy, and for this they are serving their purpose." "We are not dependent on biomarker data for a phase 2 clinical trial". "The development program for GR-MD-02 for NASH with advanced fibrosis remains on track". "Upon completion of the third cohort, which has already infused two patients, we will initiate a phase 2 clinical trial program to definitively evaluate the therapeutic potential of this promising therapy using a standard endpoint of liver biopsy to assess efficacy".
July 29, 2014
12:13 EDTGALTOn The Fly: Midday Wrap
Subscribe for More Information
11:37 EDTGALTHigh option volume stocks
Subscribe for More Information
10:39 EDTGALTGalectin drug showed no difference from placebo, The Street reports
Subscribe for More Information
08:42 EDTGALTGalectin Therapeutics drops after posting Phase I GT-020 slides
Subscribe for More Information
July 28, 2014
12:59 EDTGALTGalectin Therapeutics volatility up into Cohort 2 Phase 1 clinical trial results
Subscribe for More Information
12:44 EDTGALTGalectin pays for misleading press releases, The Street's Feuerstein says
Subscribe for More Information
11:00 EDTGALTHigh option volume stocks:
Subscribe for More Information
July 25, 2014
08:55 EDTGALTGalectin Therapeutics to host conference call
Conference call to discuss the Cohort 2 Phase 1 clinical trial results will be held on July 29 at 8:30 am. Webcast Link
July 22, 2014
10:46 EDTGALTHigh option volume stocks: SBAC KS EDU PII GALT EJ AXL TSEM HLF BCOR
Subscribe for More Information
08:44 EDTGALTGalectin Therapeutics announces first patient dosed in GR-MD-02 Phase 1B trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use